Arvind H Patel

List of Publications by Year
in descending order

50 papers	4,567 citations	186265 28 h-index	206112 48 g-index
58 all docs	58 docs citations	58 times ranked	5856 citing authors

#	Article	IF	Citations
1	Mutations that adapt SARS-CoV-2 to mink or ferret do not increase fitness in the human airway. Cell Reports, 2022, 38, 110344.	6.4	46
2	Exploration of immunological responses underpinning severe fever with thrombocytopenia syndrome virus infection reveals IL-6 as a therapeutic target in an immunocompromised mouse model. , 2022, 1, pgac024.		5
3	The Neutralizing Antibody Responses of Individuals That Spontaneously Resolve Hepatitis C Virus Infection. Viruses, 2022, 14, 1391.	3.3	0
4	SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology, 2022, 7, 1161-1179.	13.3	352
5	Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design. Npj Vaccines, 2021, 6, 7.	6.0	10
6	Diversification of mammalian deltaviruses by host shifting. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	41
7	Design and Synthesis of HCV-E2 Glycoprotein Epitope Mimics in Molecular Construction of Potential Synthetic Vaccines. Viruses, 2021, 13, 326.	3.3	2
8	A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research. PLoS Biology, 2021, 19, e3001091.	5.6	163
9	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathogens, 2021, 17, e1009929.	4.7	108
10	HCV Activates Somatic L1 Retrotranspositionâ€"A Potential Hepatocarcinogenesis Pathway. Cancers, 2021, 13, 5079.	3.7	7
11	Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. PLoS Pathogens, 2021, 17, e1010022.	4.7	139
12	Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge. Journal of Virology, 2020, 95, .	3.4	13
13	Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 2020, 370, .	12.6	508
14	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. Vaccines, 2020, 8, 307.	4.4	18
15	Improving the aqueous solubility of HCVâ€E2 glycoprotein epitope mimics by cyclization using POLAR hinges. Journal of Peptide Science, 2020, 26, e3222.	1.4	2
16	Immobilization by Surface Conjugation of Cyclic Peptides for Effective Mimicry of the HCV-Envelope E2 Protein as a Strategy toward Synthetic Vaccines. Bioconjugate Chemistry, 2018, 29, 1091-1101.	3.6	12
17	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. Nature Communications, 2018, 9, 2441.	12.8	69
18	Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data. Frontiers in Immunology, 2018, 9, 1470.	4.8	11

#	Article	IF	Citations
19	Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. MBio, 2017, 8, .	4.1	31
20	A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Antiviral Research, 2017, 148, 53-64.	4.1	18
21	KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C. Science Immunology, 2017, 2, .	11.9	78
22	Nuclear DDX3 expression predicts poor outcome in colorectal and breast cancer. OncoTargets and Therapy, 2017, Volume 10, 3501-3513.	2.0	22
23	Monoclonal antiâ€envelope antibody AP33 protects humanized mice against a patientâ€derived hepatitis C virus challenge. Hepatology, 2016, 63, 1120-1134.	7.3	30
24	Exploration of acetanilide derivatives of 1-(Ï‰-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication. Scientific Reports, 2016, 6, 29487.	3.3	15
25	Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422. Journal of Virology, 2016, 90, 3745-3759.	3.4	39
26	Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection. Journal of Virology, 2016, 90, 4530-4543.	3.4	28
27	Full Genome Sequence and sfRNA Interferon Antagonist Activity of Zika Virus from Recife, Brazil. PLoS Neglected Tropical Diseases, 2016, 10, e0005048.	3.0	193
28	Glycan Shifting on Hepatitis C Virus (HCV) E2 Glycoprotein Is a Mechanism for Escape from Broadly Neutralizing Antibodies. Journal of Molecular Biology, 2013, 425, 1899-1914.	4.2	105
29	Human Monoclonal Antibodies to a Novel Cluster of Conformational Epitopes on HCV E2 with Resistance to Neutralization Escape in a Genotype 2a Isolate. PLoS Pathogens, 2012, 8, e1002653.	4.7	201
30	Conserved Glycine 33 Residue in Flexible Domain I of Hepatitis C Virus Core Protein Is Critical for Virus Infectivity. Journal of Virology, 2012, 86, 679-690.	3.4	17
31	Toward a Hepatitis C Virus Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody. Journal of Virology, 2012, 86, 12923-12932.	3.4	89
32	Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future Microbiology, 2011, 6, 279-294.	2.0	16
33	Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. Journal of Experimental Medicine, 2010, 207, 2019-2031.	8.5	125
34	Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. Journal of General Virology, 2010, 91, 122-132.	2.9	96
35	Expression of hepatitis C virus (HCV) structural proteins in trans facilitates encapsidation and transmission of HCV subgenomic RNA. Journal of General Virology, 2009, 90, 833-842.	2.9	23
36	A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Research, 2009, 83, 148-155.	4.1	48

#	ARTICLE	IF	CITATIONS
37	Human DDX3 functions in translation and interacts with the translation initiation factor eIF3. Nucleic Acids Research, 2008, 36, 4708-4718.	14.5	158
38	Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. Journal of General Virology, 2008, 89, 653-659.	2.9	144
39	HCV requires a tight junction-associated protein for cell entry. Future Virology, 2007, 2, 335-338.	1.8	1
40	Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. Journal of General Virology, 2007, 88, 2991-3001.	2.9	61
41	Immunogenic and Functional Organization of Hepatitis C Virus (HCV) Glycoprotein E2 on Infectious HCV Virions. Journal of Virology, 2007, 81, 1043-1047.	3.4	84
42	Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding. Journal of Virology, 2006, 80, 8695-8704.	3.4	232
43	Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology, 2006, 43, 592-601.	7.3	150
44	Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein. Journal of Virology, 2005, 79, 11095-11104.	3.4	262
45	Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. Journal of General Virology, 2005, 86, 2507-2512.	2.9	28
46	Analysis of Antigenicity and Topology of E2 Glycoprotein Present on Recombinant Hepatitis C Virus-Like Particles. Journal of Virology, 2002, 76, 7672-7682.	3.4	134
47	Evidence for structural differences in the S domain of L in comparison with S protein of hepatitis B virus. Journal of General Virology, 2001, 82, 1533-1541.	2.9	5
48	Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. Journal of General Virology, 2001, 82, 1877-1883.	2.9	170
49	Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. Journal of General Virology, 2000, 81, 2873-2883.	2.9	72
50	Interaction of the herpes simplex virus type 1 packaging protein UL15 with full-length and deleted forms of the UL28 protein. Journal of General Virology, 2000, 81, 2999-3009.	2.9	41